Key Points
- Doximity CAO Siddharth Sitaram sold 2,077 shares for approximately $54,044 at an average price of $26.02. The Rule 10b5-1 transaction covered tax withholding tied to vested equity awards, reducing his ownership by 2.12% to 96,045 shares.
- Doximity reported quarterly earnings of $0.29 per share, exceeding the $0.16 analyst consensus, while revenue reached $156.62 million, up 7.3% year over year.
- Analysts maintain a generally cautious outlook, with the stock carrying a consensus “Hold” rating and an average price target of $32.18. Institutional investors own 87.19% of the company’s shares.
Doximity, Inc. (NYSE:DOCS - Get Free Report) CAO Siddharth Sitaram sold 2,077 shares of Doximity stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $26.02, for a total value of $54,043.54. Following the completion of the sale, the chief accounting officer owned 96,045 shares of the company's stock, valued at $2,499,090.90. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Siddharth Sitaram also recently made the following trade(s):
- On Thursday, August 13th, Siddharth Sitaram sold 1,770 shares of Doximity stock. The stock was sold at an average price of $24.94, for a total transaction of $44,143.80.
Doximity Price Performance
Shares of Doximity stock opened at $25.91 on Thursday. Doximity, Inc. has a 1 year low of $17.15 and a 1 year high of $76.51. The firm's 50-day moving average is $23.91 and its two-hundred day moving average is $23.12. The stock has a market cap of $4.62 billion, a price-to-earnings ratio of 30.48, a PEG ratio of 20.19 and a beta of 1.25.
Doximity (NYSE:DOCS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.13. The business had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The company's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the business posted $0.36 EPS. On average, equities analysts expect that Doximity, Inc. will post 0.74 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Weiss Ratings raised Doximity from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday. Stifel Nicolaus set a $27.00 price target on Doximity in a research report on Tuesday, September 8th. Piper Sandler restated an "overweight" rating and set a $47.00 price objective (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. Zacks Research raised Doximity from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Finally, Barclays lifted their target price on Doximity from $20.00 to $27.00 and gave the company an "equal weight" rating in a research note on Friday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $32.18.
View Our Latest Research Report on Doximity
Institutional Investors Weigh In On Doximity
Institutional investors have recently bought and sold shares of the company. Capital World Investors grew its holdings in Doximity by 5.1% in the fourth quarter. Capital World Investors now owns 5,654,875 shares of the company's stock worth $250,398,000 after purchasing an additional 273,444 shares during the last quarter. Carmignac Gestion increased its position in shares of Doximity by 127.8% during the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company's stock worth $100,480,000 after purchasing an additional 2,418,971 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Doximity by 29.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company's stock valued at $71,292,000 after purchasing an additional 694,300 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Doximity by 24.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company's stock valued at $65,022,000 after purchasing an additional 621,464 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Doximity by 3,403.2% in the 1st quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company's stock worth $32,820,000 after purchasing an additional 1,368,388 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.
Doximity Company Profile
(
Get Free Report)
Doximity, Inc operates a digital platform for U.S. medical professionals. Its network enables physicians and other healthcare providers to communicate, collaborate, access medical news and research, maintain professional profiles, and connect with colleagues and patients.
The company offers a range of tools for healthcare organizations and professionals, including telehealth services, digital faxing, scheduling and communication products, and solutions for recruiting and marketing. Doximity also provides pharmaceutical and healthcare companies with digital engagement services designed to reach medical professionals through its platform.
Founded in 2010, Doximity is headquartered in San Francisco and primarily serves the United States healthcare market.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
